ERBB2 and breast carcinoma: As we have shown that the NRG1/HER3 pathway was one of the mechanisms of acquired lapatinib resistance in HER2-overexpressing breast cancer cell lines, this pathway might also have a potential role in breast cancer cells that have innate resistance to lapatinib.